Atrial Fibrillation Drugs Market - Industry Size, Share, Growth & Forecast 2028 | UnivDatos

 Atrial fibrillation is an irregular and often very rapid heart rhythm (arrhythmia) that can lead to blood clots in the heart. A-fib increases the risk of stroke, heart failure, and other heart-related complications. The increasing prevalence of cardiovascular diseases results in an increase in the cases of atrial fibrillation which has a positive influence on the atrial fibrillation market. For instance, one person dies every 36 seconds in the United States from cardiovascular disease. About 659,000 people in the United States die from heart disease each year—that’s 1 in every 4 deaths.  Therefore, increasing demand for drugs for cardiac arrhythmia is expected to drive the global Atrial Fibrillation Drugs Market at a CAGR of 5%, during the forecast period.

Unlock The Table of Content, And Request a Sample Report - https://univdatos.com/get-a-free-sample-form-php/?product_id=27935

COVID-19 has a staggering effect on the global market. However, the market for atrial fibrillation drugs was not largely affected by the pandemic. This is mainly due to the COVID-19 pandemic, the government imposed strict regulations on healthcare institutions and essential treatments were allowed. Cardiac diseases come under essential care and the market for heart diseases did not affect by the pandemic.

 According to UnivDatos Market Insights (UMI)’ research report “global atrial fibrillation drugs market”, the market is expected to witness robust growth during the forecast period 2021-2027F. This is mainly due to the increasing demand for minimally invasive effective treatment for the rising atrial fibrillation cases.

Based on product, the market has been categorized into anticoagulant and antiarrhythmic drugs. Among them, the anticoagulant drug segment is expected to witness lucrative growth during the forecast period. Atrial fibrillation can lead to blood clots and stroke. Consecutively, anticoagulation therapy is an important method of preventing stroke in individuals with atrial fibrillation. Hence, it raises the demand for anticoagulant drugs.

Based on the disease type, the market has been categorized into paroxysmal atrial fibrillation, persistent atrial fibrillation, and longstanding persistent atrial fibrillation. Among them, the paroxysmal atrial fibrillation segment is expected to have significant growth in the market. Paroxysmal atrial fibrillation is an episode of AFib that occur occasionally and usually stops spontaneously. Episodes can last a few seconds, hours, or a few days before stopping and returning to normal sinus rhythm, which is the heart’s normal rhythm.

Unlock The Table of Content, And Request a Sample Report - https://univdatos.com/get-a-free-sample-form-php/?product_id=27935

Based on end-users, the market is segmented into hospitals, ambulatory surgical centers, and others. The hospitals are expected to witness lucrative growth during the forecast period. This is mainly due to the presence of well-qualified professionals and their specialization in the treatment of multiple diseases. Furthermore, the rising number of heart diseases and the presence of diagnostic centers and other facilities under the same roof is responsible for the segmental growth in the atrial fibrillation device market.

North America to witness extensive growth

For a better understanding of the market adoption of the atrial fibrillation drugs industry, the market is analyzed based on its worldwide presence in the countries such as North America (United States, Canada, and the Rest of North America), Europe (Germany, France, Italy, Spain, United Kingdom and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, and Rest of APAC), and Rest of World. North America constitutes a significant market for atrial fibrillation devices due to the increasing number of arrhythmia cases in the region. Furthermore, the increasing geriatric population coupled with the rising number of research studies on atrial fibrillation in the region is responsible for the regional growth in the atrial fibrillation drug market. For instance, in November 2019, N.J. & The Bristol-Myers Squibb-Pfizer Alliance announced the initiation of a new randomized, controlled study, GUARD-AF. The study seeks to determine if earlier detection of atrial fibrillation (AFib) through screening in previously undiagnosed men and women at least 70 years of age in the U.S. ultimately impacts the rate of stroke, compared to usual standard medical care.

For More Informative Information, Please Visit Us – https://univdatos.com/report/atrial-fibrillation-drugs-market/

According to UnivDatos Market Insights (UMI)’, the key players with a considerable market share in the global atrial fibrillation drugs market are Pfizer Inc., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Sanofi S.A., Bristol-Myers Squibb Company, Mitsubishi Tanabe Pharma Corporation, Johnson and Johnson, DAIICHI SANKYO COMPANY LIMITED, GlaxoSmithKline plc, and Portola Pharmaceuticals

“Global Atrial Fibrillation Drugs Market” provides comprehensive qualitative and quantitative insights on the industry potential, key factors impacting sales and purchase decisions, hotspots, and opportunities available for the market players. Moreover, the report also encompasses the key strategic imperatives for success for competitors along with strategic factorial indexing measuring competitors’ capabilities on different parameters. This will help companies in the formulation of go-to-market strategies and identifying the blue ocean for its offerings.      

Market Segmentation:

1.      By Product (Anticoagulant and Antiarrhythmic Drugs)

2.      By Disease Type (Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation, And Longstanding Persistent Atrial Fibrillation)

3.      By End-Users (Hospitals, Ambulatory Surgical Centers, and Others)

4.      By Region (North America, Europe, Asia-Pacific, Rest of the World)

5.      By Company (Pfizer Inc., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Sanofi S.A., Bristol-Myers Squibb Company, Mitsubishi Tanabe Pharma Corporation, Johnson and Johnson, DAIICHI SANKYO COMPANY LIMITED, GlaxoSmithKline plc, and Portola Pharmaceuticals.

Key questions answered in the study:

1.      What are the current and future trends of the global atrial fibrillation drugs industry?

2.      How the industry has been evolving in terms of product, disease type, and end-users?

3.      How the competition has been shaping across the countries followed by their comparative factorial indexing?

4.      What are the key growth drivers and challenges for the global atrial fibrillation drugs industry?

5.      What is the customer orientation, purchase behavior, and expectations from the global atrial fibrillation drugs suppliers across various region and countries?